Pfizer Sues to Block Generic AzaSite Sales and 2 More Heavily Traded Stocks to Follow

| + More Articles
  • Like on Facebook
  • Share on Google+
  • Share on LinkedIn

Pfizer (NYSE:PFE): Current price $29.05

Merck & Co. (NYSE:MRK) and Pfizer have sued the generic drugmaker Mylan Pharmaceuticals in order to disallow it from selling a copy of AzaSite, which is an antibiotic eye solution for combating bacterial conjunctivitis. On May 1, Mylan advised Pfizer, Merck and InSite Vision that it sought FDA clearance to sell a generic version of AzaSite, according to a lawsuit filed on Friday in federal court in Trenton, New Jersey. The complaint requests that a judge block Mylan from moving into the market prior to the patents’ expiry; one ends in 2018, and the other three in March 2019, says the FDA’s website. Pfizer holds a license with InSite to sell AzaSite, and InSite has a marketing arrangement with Inspire Pharmaceuticals, a division of Merck.

NEW! Discover a new stock idea each week for less than the cost of 1 trade. CLICK HERE for your Weekly Stock Cheat Sheets NOW!

pfe

More Articles About:

To contact the reporter on this story: staff.writers@wallstcheatsheet.com To contact the editor responsible for this story: editors@wallstcheatsheet.com

Yahoo Finance, Harvard Business Review, Market Watch, The Wall St. Journal, Financial Times, CNN Money, Fox Business